Create Account | Sign In: Author or Forum

Search Symptoms

Category: Internal Medicine | Oncology | Pathology | Institutional

Back to Journal Articles

FDA OKs Test to Improve Blood Donor-Recipient Matching

Last Updated: May 23, 2014.

The first gene-based test to help determine red blood cell compatibility between a blood donor and a recipient has been approved by the U.S. Food and Drug Administration.

FRIDAY, May 23, 2014 (HealthDay News) -- The first gene-based test to help determine red blood cell compatibility between a blood donor and a recipient has been approved by the U.S. Food and Drug Administration.

The Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test can be used to identify non-ABO red blood cell types, according to the FDA news release. The test is designed to help prevent the development of antibodies to non-ABO antigens by giving patients blood that is better matched to their non-ABO antigens. Experts say that the destruction of red blood cells can be avoided if patients with known non-ABO antigens receive blood that does not contain the same non-ABO antigens.

Current blood testing sometimes fails to detect certain non-ABO antigens. The new test offers a way to detect non-ABO antigens that may otherwise be missed, according to the FDA.

The new test is made by BioArray Solutions Ltd., of Warren, N.J.

Full Article
More Information


Previous: Targeted Biopsy May Prompt Reclassification of Prostate CA Next: Pictures, Symbols in Discharge Instructions Aid Rx Compliance

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: